Background {#Sec1}
==========

Plantar heel pain \[[@CR1]\] is a common foot condition that occurs in adults, with prevalence estimates between 4 and 7% \[[@CR2], [@CR3]\]. Several interventions are used to treat plantar heel pain, although there is limited evidence to suggest which interventions are more effective \[[@CR4]\]. Corticosteroid injection is often used to treat plantar heel pain \[[@CR5]\] but there is limited high-quality evidence to support its frequent use.

Previous systematic reviews \[[@CR6]--[@CR10]\] have summarised the effectiveness of corticosteroid injection for plantar heel pain but they have limitations, such as; not incorporating meta-analysis \[[@CR6], [@CR9]\], only including studies that compared corticosteroid injection to specific comparators \[[@CR7], [@CR8], [@CR10]\], and not evaluating the strength of the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach \[[@CR6], [@CR7], [@CR10]\]. In addition, a Cochrane Collaboration review \[[@CR11]\] that evaluated corticosteroid injection for plantar heel pain also has limitations. For example, the authors pooled data from the same intervention to different categories (e.g. for one trial, the comparator was categorised both as a control and an orthosis), reported pooled data from different outcome measures using mean differences (not standardised mean differences), and used fixed-effect models when random-effects models would have been more appropriate \[[@CR12]\]. When previous reviews are considered together, the limitations outlined above reduce the validity of their findings.

Because corticosteroid injection is frequently used to treat plantar heel pain, it is important to provide healthcare professionals with a robust summary of the findings of randomised trials, including the strength of the evidence from these trials. Accordingly, the objectives of this review were to: (i) conduct a comprehensive review of the effectiveness of corticosteroid injection on pain (including 'first step' pain), function, and plantar fascia thickness; (ii) summarise the available evidence and provide pooled effect sizes with meta-analyses; and (iii) use GRADE to evaluate the strength of the evidence.

Methods {#Sec2}
=======

This review conforms to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines \[[@CR13]\], and was prospectively registered on PROSPERO (ID = CRD42016053216).

Selection criteria {#Sec3}
------------------

Included studies had to be randomised trials (quasi-randomised trials were excluded) published in a peer-reviewed journal. Trials were included if they compared corticosteroid injection for plantar heel pain against any comparator (placebo or active treatment) and included at least one outcome measure for either pain (including 'first step' pain) or function. Trials were excluded if they compared two different corticosteroid injection techniques or provided co-interventions that were not provided to all groups.

Search strategy {#Sec4}
---------------

Electronic databases MEDLINE, CINAHL, SPORTDiscus, Embase and the Cochrane Library were searched for randomised trials published in any language. The search was originally conducted on December 1, 2016 and was updated on April 17, 2019 (Additional file [1](#MOESM1){ref-type="media"}). Complementary searches were conducted on Google Scholar and trial registries (e.g. <http://clinicaltrials.gov/>). Citation tracking was performed for identified trials and reference lists were scanned for trials that may have been missed in the original search.

Data collection {#Sec5}
---------------

Search results were exported into Endnote X7.2.1 (Thomson Reuters, New York, USA) and duplicates removed. Titles and abstracts of studies were independently screened by two authors (GAW and JMG), and studies that did not meet the inclusion criteria were excluded. Full-text articles were obtained for remaining studies and these were examined for eligibility based on the inclusion criteria.

A data extraction form was used to extract trial characteristics and outcome data. Primary outcomes were pain (including 'first step' pain) and function. One secondary outcome was included, which was plantar fascia thickness. Other information including variables affecting bias, adverse effects and characteristics of the corticosteroid injections were also extracted. One author (GAW) extracted data and a random sample of 25% of the trials were analysed by a second author (JMG) to ensure extracted data were error free. The mean, sample size and standard deviation of outcome measures at time-points categorised as *short term* (0 to 6 weeks), *medium term* (7 to 12 weeks) and *longer term* (13 to 52 weeks) were extracted. Attempts were made to obtain missing data by contacting authors. If no response was received, missing standard deviations were calculated based on *P* values if possible \[[@CR14]\]. Any remaining trials for which standard deviations were not available were imputed using pooled standard deviations from other trials in the meta-analysis \[[@CR15]\].

Data handling and analysis {#Sec6}
--------------------------

All data were synthesised and analysed using RevMan (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Trials were grouped for meta-analysis based on the comparator intervention. For trials that used multiple measures to evaluate the same outcome (such as pain measured on separate questionnaires), the primary outcome measure was used. If more than two trials compared corticosteroid injection to the same comparator with the same time-points for outcome assessment, the data were pooled for a meta-analysis.

Due to the design variability of the included trials, an inverse-variance random-effects model was applied to all meta-analyses \[[@CR12]\]. Outcome measures for which a higher score indicated less pain or improved function were multiplied by − 1 to provide common directionality of results. The relative treatment effect for each study was estimated by calculating the standardised mean difference (SMD), even if trials used the same outcome measure, to consistently present findings across different meta-analyses. The SMD was interpreted as having a small effect if approximately 0.2, a moderate effect if 0.5, a large effect if 0.8 and a very large effect if 1.3 \[[@CR16]\]. Heterogeneity was investigated using the *Chi*^*2*^ and *I*^*2*^ statistics \[[@CR17]\].

Assessment of study quality {#Sec7}
---------------------------

Risk of bias assessment was performed independently by two authors (SEM and DRB) using the Cochrane Collaboration tool for assessing risk of bias and disagreements were resolved by consensus meeting \[[@CR14]\]. A trial was considered to have a high risk of bias if at least one of the criteria was rated high risk. To be considered low risk of bias, all criteria had to be rated low risk. Any trials not meeting these criteria were considered unclear. The agreement between reviewers was evaluated by calculating a weighted kappa coefficient \[[@CR18]\] using the *kap* command in Stata (version 16.0, StataCorp LLC, College Station, TX). A sensitivity analysis was conducted that excluded trials considered to be at high risk of bias to assess the impact on the original meta-analysis.

Assessment of trial quality at the outcome level was undertaken using GRADE \[[@CR19]\]. The criteria used to make judgements for each criterion are outlined in Additional file [2](#MOESM2){ref-type="media"}.

Results {#Sec8}
=======

The systematic search identified 47 articles, and at the conclusion of screening, 47 individual trials were included in the final review (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR20]--[@CR66]\]. Data were unable to be obtained from three trials \[[@CR32], [@CR48], [@CR55]\] after contacting the authors, and five trials \[[@CR33], [@CR34], [@CR37], [@CR47], [@CR53]\] could not be included in meta-analyses as the data were from composite outcome measures. Data from a four group trial \[[@CR56]\] that sub-divided participants on the presence of perifascial oedema were combined to two groups so the data were similar to other trials. Finally, one trial \[[@CR33]\] reported medians and interquartile ranges, which were converted to means and standard deviations \[[@CR67]\]. Fig. 1Flow of studies through the review

The combined sample size from the included trials was 2989; 65.1% of participants were female, mean age 46.5 years and mean body mass index (BMI) 28.9 kg/m^2^. Each trial's intervention, comparator, and participant characteristics are summarised in Table [1](#Tab1){ref-type="table"}. The mean group size from the included trials was 28. Characteristics of the corticosteroid injections are summarised in Table [2](#Tab2){ref-type="table"}; there were eight different types of corticosteroid used, with methylprednisolone acetate the most common (23/47 trials). Most trials (38/47) reported that they mixed a corticosteroid with a local anaesthetic and lidocaine was the most common (25/47 trials). A variety of injection techniques were used, most commonly without ultrasound guidance (35/47 trials) and by injecting at the point of maximal tenderness (14/47 trials). Table 1Descriptive characteristics of trials included in the reviewTrialInterventionComparatorCointerventionsParticipants per groupFemale participants (%)Mean age (years)Mean BMI (kg/m^2^)Duration of symptoms (weeks)^a^Trial duration (weeks)Trial settingInterventionComparatorAbdihakin (2012) \[[@CR20]\]Corticosteroid injectionPlacebo injectioni) Oral anti-inflammatory drugs three times daily;ii) stretches;iii) foot orthoses;iv) heel splints;v) shoe recommendations44385242.931.7NR12Outpatient clinicAcosta-Olivo (2017) \[[@CR21]\]Corticosteroid injectionPlatelet-rich plasma injectionPlantar fascia stretches14148044.8NR\>  12 weeks16Outpatient clinicAfsar (2015) \[[@CR22]\]Corticosteroid injectionAutologous blood injectionNone62615731.8NR\>  12 weeks24Outpatient clinicBabaei-Ghazani (2019) \[[@CR23]\]Corticosteroid injectionOzone injectionPlantar fascia and calf stretches15159046.329.0\>  8 weeks12Outpatient clinicBall (2012) \[[@CR24]\]Corticosteroid injectionPlacebo injectionPermitted to use analgesia if required22195649.431.6\>  8 weeks12Rheumatology serviceCelik (2015) \[[@CR25]\]Corticosteroid injectionPhysical therapyNone21226545.530.0NR52HospitalCrawford (1999) \[[@CR26]\]Corticosteroid injectionLocal anaesthetic injectionNR27276557.0NRNR26HospitalCorticosteroid injection + tibial nerve blockLocal anaesthetic injection + tibial nerve block2626Diaz-Llopis (2012) \[[@CR27]\]Corticosteroid injectionBotulinum toxin-A injectionPlantar fascia and calf stretches28286653.9NR\>  26 weeks4HospitalElizondo-Rodriguez (2013) \[[@CR28]\]Corticosteroid injectionBotulinum toxin-A injectionPlantar fascia stretches17175543.0NR\>  12 weeks26HospitalEslamian (2016) \[[@CR29]\]Corticosteroid injectionExtracorporeal shockwave therapyi) Foot orthoses and heel pads;ii) plantar fascia and calf stretches20208242.1NR\>  8 weeks8HospitalGuevara Serna (2017) \[[@CR30]\]Corticosteroid injectionExtracorporeal shockwave therapyNR24366751.0NR\>  12 weeks52HospitalGuner (2013) \[[@CR31]\]Corticosteroid injectionTenoxicam injectionA stretching and strengthening program30317741.429.5\>  12 weeks52NRHanselman (2015) \[[@CR32]\]Corticosteroid injectionCryopreserved human amniotic membranePlantar fascia and calf stretches1497051.0NR\>  12 weeks18NRHocaoglu (2017) \[[@CR33]\]Corticosteroid injectionExtracorporeal shockwave therapyNR36368749.028.7\>  26 weeks26Outpatient clinicHou (2018) \[[@CR34]\]Corticosteroid injectionExtracorporeal shockwave therapyNR39383541.525.4\>  12 weeks26HospitalJain (2015) \[[@CR35]\]Corticosteroid injectionPlatelet-rich plasma injectioni) Eccentric stretches;ii) foot orthoses22246555.6NR\>  52 weeks52HospitalJain (2018) \[[@CR36]\]Corticosteroid injectionPlatelet-rich plasma injectionPlantar fascia and calf stretches40404238.324.1\>  12 weeks26HospitalJohannsen (2019) \[[@CR37]\]Corticosteroid injectionPhysical therapyNR31305845.026.2\>  12 weeks104UniversityCorticosteroid injection + physical therapy29Karimzadeh (2017) \[[@CR38]\]Corticosteroid injectionControl groupPlantar fascia stretches12126747.5NR\>  8 weeks12NRAutologous blood injection12Kiter (2006) \[[@CR39]\]Corticosteroid injectionAutologous blood injectionNR14156950.7NR\>  26 weeks26UniversityKriss (2003) \[[@CR40]\]Corticosteroid injectionFoot orthosesNR22266059.3NRNR26NRCorticosteroid injection + foot orthoses31Lai (2018) \[[@CR41]\]Corticosteroid injectionExtracorporeal shockwave therapyAcetaminophen as required50475653.5NR\>  4 weeks12HospitalLee (2007) \[[@CR42]\]Corticosteroid injectionAutologous blood injectionPlantar fascia and calf stretches31309348.726.1\>  6 weeks26Outpatient clinicLi (2014) \[[@CR43]\]Corticosteroid injectionMiniscalpel needleParticipants were permitted to continue with any conservative treatment30317255.8NR\>  26 weeks52HospitalMahindra (2016) \[[@CR44]\]Corticosteroid injectionPlacebo injectionPlantar fascia and calf stretches25255833.4NR\>  12 weeks12NRPlatelet-rich plasma injection25Mardani-Kivi (2015) \[[@CR45]\]Corticosteroid injectionExtracorporeal shockwave therapyNone41408444.329.6\<  6 weeks12UniversityMcMillan (2012) \[[@CR46]\]Corticosteroid injectionPlacebo injectionPlantar fascia stretches41414852.631.1\>  8 weeks12UniversityMonto (2014) \[[@CR47]\]Corticosteroid injectionPlatelet-rich plasma injectioni) CAM walker for two weeks;ii) Swedish heel drop program;iii) plantar fascia and calf stretches20205755.029.2\>  16 weeks104NRMulherin (2009) \[[@CR48]\]Corticosteroid injectionTibial nerve block14126055 (median)NRNR26Community medical centreCorticosteroid injection + tibial nerve block19Omar (2012) \[[@CR49]\]Corticosteroid injectionPlatelet-rich plasma injectionNR151510043.5NRNR6HospitalPorter (2005) \[[@CR50]\]Corticosteroid injectionExtracorporeal shockwave therapyPlantar fascia and calf stretches64616639.2NR\>  6 weeks52HospitalRastegar (2018) \[[@CR51]\]Corticosteroid injectionDry-needlingNR34325840.9NR\>  12 weeks52UniversityRyan (2014) \[[@CR52]\]Corticosteroid injectionPhysical therapyCalf stretches28285749.325.2\>  52 weeks12UniversitySaber (2012) \[[@CR53]\]Corticosteroid injectionExtracorporeal shockwave therapyNR30305534.229.0\>  26 weeks12Outpatient clinicSerbest (2013) \[[@CR54]\]Corticosteroid injectionExtracorporeal shockwave therapyNR15155345.230.5\>  6 weeks12Sports medicine clinicShetty (2019) \[[@CR55]\]Corticosteroid injectionPlacebo injectioni) Oral enterocoxib and paracetamol for 5 days;ii) plantar fascia stretches;iii) eccentric calf strengthening30305444.6NR\>  12 weeks78HospitalPlatelet-rich plasma injection30Sorrentino (2008) \[[@CR56]\]Corticosteroid injection in participants with perifascial oedemaExtracorporeal shockwave therapyNR161556NR27.9\>  8 weeks6UniversityCorticosteroid injection in participants without perifascial oedemaExtracorporeal shockwave therapy1516Tiwari (2013) \[[@CR57]\]Corticosteroid injectionPlatelet-rich plasma injectionNR3030NRNRNRNR26HospitalUgurlar (2018) \[[@CR58]\]Corticosteroid injectionPlatelet-rich plasma injectionAcetaminophen for 3 days40395038.826.9\>  52 weeks156HospitalExtracorporeal shockwave therapyProlotherapy3940Uygur (2018) \[[@CR59]\]Corticosteroid injectionDry-needlingNR47496649.6NR\>  12 weeks26HospitalVahdatpour (2016) \[[@CR60]\]Corticosteroid injectionPlatelet-rich plasma injectionPlantar fascia and calf stretches16167246.229.6\>  12 weeks26HospitalWhittaker (2019) \[[@CR61]\]Corticosteroid injectionFoot orthosesPlantar fascia and calf stretches50536143.930.4\>  4 weeks12UniversityYesiltas (2015) \[[@CR62]\]Corticosteroid injectionAutologous blood injectionNR21285745.530.4NR26HospitalYucel (2010) \[[@CR63]\]Corticosteroid injectionExtracorporeal shockwave therapyNone permitted other than heel cups33277043.9NR\>  26 weeks12NRYucel (2013) \[[@CR64]\]Corticosteroid injectionFoot orthosesAnalgesia if required20208046.430.1\>  12 weeks4UniversityYuzer (2006) \[[@CR65]\]Corticosteroid injectionLaser therapyNR30248550.532.3\>  4 weeks26NRZamani (2014) \[[@CR66]\]Corticosteroid injectionLaser therapyNR20205752.5NR\>  6 weeks6Rheumatology clinic*Abbreviations*: *NR* Not reported, *BMI* Body mass index^a^The minimum duration of symptoms that was specified in the inclusion criteria for the trial Table 2Characteristics of the corticosteroid injection used in each trialTrialDrugLocal anaestheticUltrasound guidanceNeedle placementAbdihakin (2012) \[[@CR20]\]Methylprednisolone acetateLidocaine 1%NoNRAcosta-Olivo (2017) \[[@CR21]\]Dexamethasone isonicotinateLidocaine^a^NoPoint of maximal tendernessAfsar (2015) \[[@CR22]\]NRLidocaine 1%NoNRBabaei-Ghazani (2019) \[[@CR23]\]Methylprednisolone acetateLidocaine 1%YesWithin the plantar fasciaBall (2012) \[[@CR24]\]Methylprednisolone acetateNone. Skin anesthetizedYesSuperficial to the plantar fascia enthesisCelik (2015) \[[@CR25]\]Methylprednisolone acetatePrilocaine 2%NoAround the plantar fasciaCrawford (1999) \[[@CR26]\]Prednisolone acetateLidocaine 1%NoWithin flexor digitorum brevisDiaz-Llopis (2012) \[[@CR27]\]Betamethasone acetate and betamethasone disodium phosphateMepivacaine 1%NoDeep to quadratus plantae, near the plantar fascia insertionElizondo-Rodriguez (2013) \[[@CR28]\]Dexamethasone isonicotinateLidocaine 2%NoSuperior to the plantar fasciaEslamian (2016) \[[@CR29]\]Methylprednisolone acetateLidocaine 2%NoNRGuevara Serna (2017) \[[@CR30]\]Methylprednisolone acetateLidocaine^a^NoPoint of maximal tendernessGuner (2013) \[[@CR31]\]Methylprednisolone acetateLidocaine 2%NoPeppering the plantar fasciaHanselman (2015) \[[@CR32]\]Methylprednisolone acetateBupivacaine 0.5%NoInserted to calcaneal periosteum then 'dragged' across plantar fasciaHocaoglu (2017) \[[@CR33]\]Betamethasone sodium phosphatePrilocaine^a^YesInto the thickest part of the plantar fascia, distal to its insertion on the calcaneusHuo (2018) \[[@CR34]\]Betamethasone^a^Lidocaine 2%YesWithin the thickest part of the plantar fasciaJain (2015) \[[@CR35]\]Triamcinolone acetonideLevobupivacaine^a^NoPeppering the plantar fasciaJain (2018) \[[@CR36]\]Methylprednisolone acetateLidocaine 2%NoPoint of maximal tendernessJohannsen (2019) \[[@CR37]\]Methylprednisolone acetateLidocaine 1%YesNRKarimzadeh (2017) \[[@CR38]\]Methylprednisolone acetateLidocaine^a^NoPoint of maximal tendernessKiter (2006) \[[@CR39]\]Methylprednisolone acetatePrilocaine 2%NoNRKriss (2003) \[[@CR40]\]Triamcinolone hexacetonideNRNoNRLai (2018) \[[@CR41]\]Triamcinolone acetonideLidocaine 2%NoNRLee (2007) \[[@CR42]\]Triamcinolone acetonideLidocaine 1%NoOrigin of the plantar fasciaLi (2014) \[[@CR43]\]Triamcinolone acetonideLidocaine 2%NoPoint of maximal tendernessMahindra (2016) \[[@CR44]\]Methylprednisolone acetateNRNoPeppering the plantar fasciaMardani-Kivi (2015) \[[@CR45]\]Methylprednisolone acetateLidocaine 2%NoPoint of maximal tendernessMcMillan (2012) \[[@CR46]\]Dexamethasone sodium phosphateNil -- provided tibial blockYesWithin the plantar fasciaMonto (2014) \[[@CR47]\]Methylprednisolone acetateField block to the skin of bupivacaine 0.5%YesNRMulherin (2009) \[[@CR48]\]Methylprednisolone^a^Lidocaine 1%NoWithin the plantar fasciaOmar (2012) \[[@CR49]\]NRNRNoNRPorter (2005) \[[@CR50]\]Betamethasone^a^Lidocaine 1%NoPoint of maximal tendernessRastegar (2018) \[[@CR51]\]Methylprednisolone acetateNRNoPoint of maximal tendernessRyan (2014) \[[@CR52]\]Dexamethasone^a^Lidocaine 1%NoPoint of maximal tendernessSaber (2012) \[[@CR53]\]Betamethasone diproprionate and betamethasone sodium phosphateLidocaine 0.5%YesWithin the plantar fasciaSerbest (2013) \[[@CR54]\]Betamethasone acetate and betamethasone sodium phosphatePrilocaine 2%NoPoint of maximal tendernessShetty (2019) \[[@CR55]\]Methylprednisolone acetateLidocaine 1%NoPeppering the point of maximal tendernessSorrentino (2008) \[[@CR56]\]Methylprednisolone acetateMepivacaine 3%YesWithin the plantar fasciaTiwari (2013) \[[@CR57]\]Methylprednisolone acetateLidocaine 2%NoPoint of maximal tendernessUgurlar (2018) \[[@CR58]\]Betamethasone^a^Bupivacaine 0.5%YesPoint of maximal tendernessUygur (2018) \[[@CR59]\]Methylprednisolone acetateBupivacaine 0.5%NoBetween the plantar fascia and the periosteum, with pepperingVahdatpour (2016) \[[@CR60]\]Methylprednisolone acetateLidocaine^a^NoPoint of maximal tendernessWhittaker (2019) \[[@CR61]\]Betamethasone acetate and betamethasone sodium phosphateBupivacaine 0.5%YesDeep and superficial to the plantar fasciaYesiltas (2015) \[[@CR62]\]Triamcinolone^a^ (mixed with distilled water)NRNoNRYucel (2010) \[[@CR63]\]Betamethasone diproprionate and betamethasone sodium phosphatePrilocaine 2%NoPoint of maximal tendernessYucel (2013) \[[@CR64]\]Betamethasone diproprionate and betamethasone sodium phosphateLidocaine^a^YesWithin the plantar fasciaYuzer (2006) \[[@CR65]\]Betamethasone diproprionate and betamethasone sodium phosphatePrilocaine 2%NoPoint of maximal tendernessZamani (2014) \[[@CR66]\]Methylprednisolone acetateNRNoPoint of maximal tenderness*Abbreviations*: *NR* Not reported^a^No other information provided

Risk of bias assessment (Fig. [2](#Fig2){ref-type="fig"}) revealed that 1/47 of the included trials was low risk, 41/47 were high risk, and 5/47 were of unclear risk. A frequent contributor (39/47 trials) to high risk of bias was not blinding participants/personnel and outcome assessors. There was a moderate \[[@CR18]\] level of agreement between the authors (SEM and DRB) who assessed risk of bias (*κ* = 0.46; 95% CI, 0.40 to 0.50, *P* \< 0.001). Fig. 2Risk of bias summary for each included trial

GRADE evidence profiles are presented in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Ratings were made at short, medium and longer term-time points for comparisons that had sufficient data to conduct meta-analyses. Ratings were only made for the primary outcomes of pain and function as they were considered the most important outcomes for patients \[[@CR68]\]. Table 3GRADE evidence profile of the effect of corticosteroid injection on painQuality assessmentSummary of findingsComparisonNo. of trialsLimitationsInconsistencyIndirectnessImprecisionPublication biasParticipantsEffect size\
(95% CI)^a^GRADECorticosteroid injectionComparatorCorticosteroid injection vs placebo injection Short term4 \[[@CR20], [@CR24], [@CR44], [@CR46]\]No serious limitationsSerious inconsistency^b^No serious indirectnessSerious imprecision^c^Undetected132123-0.98(−2.06, 0.11)^f^Moderate Medium term4 \[[@CR20], [@CR24], [@CR44], [@CR46]\]No serious limitationsSerious inconsistency^b^No serious indirectnessSerious imprecision^c^Undetected126122-0.86(− 1.90, 0.19)^f^ModerateCorticosteroid injection vs physical therapy Short term2 \[[@CR25], [@CR52]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessSerious imprecision^e^Undetected4950-1.07(−2.75, 0.60)^f^Very low Medium term3 \[[@CR25], [@CR37], [@CR52]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessNo serious imprecisionUndetected8079-0.74(− 1.51, 0.03)^f^Low Longer term2 \[[@CR25], [@CR37]\]Very serious limitations^d^No serious inconsistencyNo serious indirectnessSerious imprecision^c^Undetected52510.00(−0.39, 0.38)Very lowCorticosteroid injection vs foot orthoses Short term3 \[[@CR40], [@CR61], [@CR64]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessNo serious imprecisionUndetected9299−0.91(−1.69, − 0.13)^f^Low Medium term3 \[[@CR40], [@CR61], [@CR64]\]Very serious limitations^d^Serious inconsistency^b^Serious indirectness^g^Serious imprecision^c^Undetected7279−0.17(− 1.30, 0.97)Very lowCorticosteroid injection vs dry needling Short term2 \[[@CR51], [@CR59]\]Very serious limitations^d^Very serious inconsistency^b^No serious indirectnessSerious imprecision^c^Undetected8181−0.86(−3.70, 1.97)^f^Very low Longer term2 \[[@CR51], [@CR59]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessNo serious imprecisionUndetected81811.45 (0.70, 2.19)^f^LowCorticosteroid injection vs extracorporeal shockwave therapy Short term8 \[[@CR29], [@CR33], [@CR34], [@CR41], [@CR45], [@CR54], [@CR56], [@CR58]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessNo serious imprecisionUndetected269265−0.32(−0.77, 0.12)Very low Medium term10 \[[@CR29], [@CR30], [@CR33], [@CR34], [@CR41], [@CR45], [@CR50], [@CR54], [@CR58], [@CR63]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessSerious imprecision^c^Undetected354354−0.05(−0.60, 0.49)Very low Longer term5 \[[@CR30], [@CR33], [@CR34], [@CR50], [@CR58]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessNo serious imprecisionUndetected2022110.45(−0.09, 0.99)Very lowCorticosteroid injection vs laser therapy Short term2 \[[@CR65], [@CR66]\]Very serious limitations^d^No serious inconsistencySerious indirectness^g^Serious imprecision^c^Undetected5044−0.20(−0.61, 0.20)Very lowCorticosteroid injection vs autologous blood injection Short term4 \[[@CR22], [@CR38], [@CR42], [@CR62]\]Very serious limitations^d^No serious inconsistencyNo serious indirectnessNo serious imprecisionUndetected126131−0.56(−0.86, − 0.26)Low Medium term4 \[[@CR22], [@CR38], [@CR42], [@CR62]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessSerious imprecision^c^Undetected126131−0.31(−0.83, 0.21)Very low Longer term4 \[[@CR22], [@CR39], [@CR42], [@CR62]\]Very serious limitations^d^No serious inconsistencyNo serious indirectnessSerious imprecision^c^Undetected128134−0.05(−0.31, 0.21)Very lowCorticosteroid injection vs platelet-rich plasma injection Short term8 \[[@CR21], [@CR35], [@CR36], [@CR44], [@CR49], [@CR57], [@CR58], [@CR60]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessSerious imprecision^c^Undetected202203−0.16(−0.70, 0.38)Very low Medium term7 \[[@CR21], [@CR35], [@CR36], [@CR44], [@CR57], [@CR58], [@CR60]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessSerious imprecision^c^Undetected1871880.32(−0.19, 0.83)Very low Longer term6 \[[@CR21], [@CR35], [@CR36], [@CR57], [@CR58], [@CR60]\]Very serious limitations^d^Serious inconsistency^b^Serious indirectness^h^No serious imprecisionUndetected1621630.61 (0.30, 1.06)Very lowCorticosteroid injection vs botulinum toxin-A injection Short term2 \[[@CR27], [@CR28]\]Very serious limitations^d^Serious inconsistency^b^No serious indirectnessSerious imprecision^e^Undetected45450.67(−0.04, 1.38)Very low*Abbreviations*: *CI* Confidence interval, *GRADE* Grading Recommendations Assessment, Development and Evaluation^a^ Negative values indicate that the effect size (SMD) favours corticosteroid injection^b^ Rated down 1 level for consistency as there was significant heterogeneity (i.e. *I*^2^ greater than 40%)^c^ Rated down 1 level as the upper and lower boundaries of the confidence intervals represent different conclusions^d^ All participants for this outcome were from trials rated at high risk of bias^e^ The total sample for this outcome is less than 100^f^ Rated up 1 level due to large effect size^g^ The interventions differed between studies^h^ Outcome measures were obtained at significantly different time points Table 4GRADE evidence profile of the effect of corticosteroid injection on functionQuality assessmentSummary of findingsComparisonNo. of trialsLimitationsInconsistencyIndirectnessImprecisionPublication biasParticipantsEffect size\
(95% CI)^a^GRADECorticosteroid injectionComparatorCorticosteroid injection vs physical therapy Short term2 \[[@CR25], [@CR52]\]Very serious limitations^b^Serious inconsistency^c^No serious indirectnessNo serious imprecisionUndetected4950−0.69 (−1.31, − 0.07)Low Medium term2 \[[@CR25], [@CR52]\]Very serious limitations^b^Serious inconsistency^c^No serious indirectnessSerious imprecision^d^Undetected4950−0.55 (− 1.14, 0.03)Very lowCorticosteroid injection vs foot orthoses Short term2 \[[@CR61], [@CR64]\]Very serious limitations^b^Serious inconsistency^c^No serious indirectnessSerious imprecision^d^Undetected7073−0.78 (−1.81, 0.25)Very lowCorticosteroid injection vs extracorporeal shockwave therapy Short term2 \[[@CR41], [@CR58]\]Very serious limitations^b^No serious inconsistencyNo serious indirectnessSerious imprecision^d^Undetected90860.11 (−0.18, 0.41)Very low Medium term2 \[[@CR41], [@CR58]\]Very serious limitations^b^No serious inconsistencyNo serious indirectnessSerious imprecision^d^Undetected90860.21 (−0.08, 0.51)Very lowCorticosteroid injection vs platelet-rich plasma injection Short term3 \[[@CR21], [@CR36], [@CR58]\]Very serious limitations^b^No serious inconsistencyNo serious indirectnessNo serious imprecisionUndetected9493−0.18 (−0.47, 0.10)Low Medium term3 \[[@CR21], [@CR36], [@CR58]\]Very serious limitations^b^No serious inconsistencyNo serious indirectnessSerious imprecision^d^Undetected94930.10(−0.18, 0.39)Very low Longer term3 \[[@CR21], [@CR36], [@CR58]\]Very serious limitations^b^No serious inconsistencyNo serious indirectnessNo serious imprecisionUndetected94930.21 (−0.08, 0.49)LowCorticosteroid injection vs botulinum toxin-A injection Short term2 \[[@CR27], [@CR28]\]Very serious limitations^b^Serious inconsistency^c^No serious indirectnessSerious imprecision^d^Undetected45450.76 (−0.24, 1.76)Very low*Abbreviations*: *CI* Confidence interval, *GRADE* Grading Recommendations Assessment, Development and Evaluation^a^ Negative values indicate that the effect size (SMD) favours corticosteroid injection^b^ All participants for this outcome were from trials rated at high risk of bias^c^ Rated down 1 level for consistency as there was significant heterogeneity (i.e. *I*^2^ greater than 40%)^d^ Rated down 1 level as the upper and lower boundaries of the confidence intervals represent different conclusions

Primary outcomes {#Sec9}
----------------

### Pain {#Sec10}

Results of trials that could not be pooled in meta-analyses are summarised in Additional file [3](#MOESM3){ref-type="media"}. Pooled point estimates with negative values indicate an effect in favour of corticosteroid injection.

Data for the comparison of corticosteroid injection to placebo injection were available from four trials \[[@CR20], [@CR24], [@CR44], [@CR46]\] in the short and medium terms, and no data were available in the longer term (Fig. [3](#Fig3){ref-type="fig"}). There was moderate quality evidence that corticosteroid injection is similar to placebo injection in the short (SMD -0.98; 95% CI, − 2.06 to 0.11) and medium terms (SMD -0.86; 95% CI, − 1.90 to 0.19). Fig. 3Meta-analyses comparing corticosteroid injection to placebo injection for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval*

When corticosteroid injection was compared to other comparators in the short term (0 to 6 weeks), there was low quality evidence that corticosteroid injection is more effective than autologous blood injection (SMD -0.56; 95% CI, − 0.86 to − 0.26) (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR22], [@CR38], [@CR42], [@CR62]\] and foot orthoses (SMD -0.91; 95% CI, − 1.69 to − 0.13) (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR40], [@CR61], [@CR64]\]. There was very-low quality evidence that corticosteroid injection is similar to physical therapy (SMD -1.07; 95% CI, − 2.75 to 0.60) (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR25], [@CR52]\], dry needling (SMD -0.86; 95% CI, − 3.70 to 1.97) (Fig. [7](#Fig7){ref-type="fig"}) \[[@CR51], [@CR59]\], botulinum toxin-A injection (SMD 0.67; 95% CI, − 0.04 to 1.38) (Fig. [8](#Fig8){ref-type="fig"}) \[[@CR27], [@CR28]\], platelet-rich plasma injection (SMD -0.16; 95% CI, − 0.70 to 0.38) (Fig. [9](#Fig9){ref-type="fig"}) \[[@CR21], [@CR35], [@CR36], [@CR44], [@CR49], [@CR57], [@CR58], [@CR60]\], extracorporeal shockwave therapy (SMD -0.32; 95% CI, − 0.77 to 0.12) (Fig. [10](#Fig10){ref-type="fig"}) \[[@CR29], [@CR33], [@CR34], [@CR41], [@CR45], [@CR54], [@CR56], [@CR58]\], laser therapy (SMD -0.20; 95% CI, − 0.61 to 0.20) (Fig. [11](#Fig11){ref-type="fig"}) \[[@CR65], [@CR66]\], and local anaesthetic injection (SMD -0.34; 95% CI, − 0.73 to 0.04) (Fig. [12](#Fig12){ref-type="fig"}) \[[@CR26]\]. Fig. 4Meta-analyses comparing corticosteroid injection to autologous blood injection for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 5Meta-analyses comparing corticosteroid injection to foot orthoses for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 6Meta-analyses comparing corticosteroid injection to physical therapy for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 7Meta-analyses comparing corticosteroid injection to dry needling for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 8Meta-analyses comparing corticosteroid injection to botulinum toxin-A injection for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 9Meta-analyses comparing corticosteroid injection to platelet-rich plasma injection for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 10Meta-analyses comparing corticosteroid injection to extracorporeal shockwave therapy for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 11Meta-analyses comparing corticosteroid injection to laser therapy for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 12Meta-analyses comparing corticosteroid injection to local anaesthetic injection for the outcome of pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval*

In the medium term (7 to 12 weeks), there was low quality evidence that corticosteroid injection is similar to physical therapy (SMD -0.74; 95% CI, − 1.51 to 0.03) \[[@CR25], [@CR37], [@CR52]\], and very-low quality evidence corticosteroid injection is similar to autologous blood injection (SMD -0.31; 95% CI, − 0.83 to 0.21) \[[@CR22], [@CR38], [@CR42], [@CR62]\], foot orthoses (SMD -0.17; 95% CI; − 1.30 to 0.97) \[[@CR40], [@CR61]\], platelet-rich plasma injection (SMD 0.32; 95% CI, − 0.19 to 0.83) \[[@CR21], [@CR35], [@CR36], [@CR44], [@CR57], [@CR58], [@CR60]\], extracorporeal shockwave therapy (SMD -0.05; 95% CI, − 0.60 to 0.49) \[[@CR29], [@CR30], [@CR33], [@CR34], [@CR41], [@CR45], [@CR50], [@CR54], [@CR58], [@CR63]\], and local anaesthetic injection (SMD 0.04; 95% CI, − 0.34 to 0.42) \[[@CR26]\].

In the longer term (13 to 52 weeks), there was low quality evidence that corticosteroid injection is less effective than dry needling (SMD 1.45; 95% CI, 0.70 to 2.19) \[[@CR51], [@CR59]\], and very low-quality evidence corticosteroid injection is less effective than platelet-rich plasma injection (SMD 0.61; 95% CI, 0.16 to 1.06) \[[@CR21], [@CR35], [@CR36], [@CR57], [@CR58], [@CR60]\]. There was very-low quality evidence that corticosteroid injection is similar to physical therapy (SMD -0.00; 95% CI − 0.39 to 0.38) \[[@CR25], [@CR37]\] autologous blood injection (SMD -0.05; 95% CI, − 0.31 to 0.21) \[[@CR22], [@CR39], [@CR42], [@CR62]\], extracorporeal shockwave therapy (SMD 0.45; 95% CI, − 0.09 to 0.99) \[[@CR30], [@CR33], [@CR34], [@CR50], [@CR58]\], and local anaesthetic injection (SMD 0.22; 95% CI, − 0.87 to 1.31) \[[@CR26]\].

For 'first-step' pain, meta-analyses were possible for trials that compared corticosteroid injection to placebo injection in the short and medium terms (Fig. [13](#Fig13){ref-type="fig"}). Corticosteroid injection was similar to placebo injection in the short (SMD -0.33; 95% CI, − 0.68 to 0.01) and medium terms (SMD -0.05; 95% CI, − 0.46 to 0.36) \[[@CR20], [@CR46]\]. Results from trials that could not be pooled in meta-analyses are summarised in Additional file [4](#MOESM4){ref-type="media"}. Fig. 13Meta-analyses comparing corticosteroid injection to placebo injection for the outcome of 'first step' pain. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval*

### Function {#Sec11}

In the short term, there was low quality evidence that corticosteroid injection is more effective than physical therapy (SMD -0.69; 95% CI, − 1.31 to − 0.07) (Fig. [14](#Fig14){ref-type="fig"}) \[[@CR25], [@CR52]\]. There was very-low quality evidence that corticosteroid injection is similar to foot orthoses (SMD -0.78; 95% CI, − 1.81 to 0.25) (Fig. [15](#Fig15){ref-type="fig"}) \[[@CR61], [@CR64]\], extracorporeal shockwave therapy (SMD 0.11; 95% CI, − 0.18 to 0.41) (Fig. [16](#Fig16){ref-type="fig"}) \[[@CR41], [@CR58]\], and botulinum toxin-A injection (SMD 0.76; 95% CI, − 0.24 to 1.76) (Fig. [17](#Fig17){ref-type="fig"}) \[[@CR27], [@CR28]\]. There was low quality evidence that corticosteroid injection is similar to platelet-rich plasma injection (SMD -0.18; 95% CI − 0.47 to 0.10) (Fig. [18](#Fig18){ref-type="fig"}) \[[@CR21], [@CR36], [@CR58]\], Fig. 14Meta-analyses comparing corticosteroid injection to physical therapy for the outcome of function. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 15Meta-analyses comparing corticosteroid injection to foot orthoses for the outcome of function. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 16Meta-analyses comparing corticosteroid injection to extracorporeal shockwave therapy for the outcome of function. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 17Meta-analyses comparing corticosteroid injection to botulinum toxin-A injection for the outcome of function. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval* Fig. 18Meta-analyses comparing corticosteroid injection to platelet-rich plasma injection for the outcome of function. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval*

In the medium term, there was very-low quality evidence that corticosteroid injection is similar to physical therapy (SMD -0.55; 95% CI, − 1.14 to 0.03) \[[@CR25], [@CR52]\], extracorporeal shockwave therapy (SMD 0.21; 95% CI − 0.08 to 0.51) \[[@CR41], [@CR58]\], and platelet-rich plasma injection (SMD 0.10; 95% CI, − 0.18 to 0.39) \[[@CR21], [@CR36], [@CR58]\].

In the longer term, there was low quality evidence that corticosteroid injection is similar to platelet-rich plasma injection (SMD 0.21; 95% CI, − 0.08 to 0.49) \[[@CR21], [@CR36], [@CR58]\]. Results of trials that could not be pooled in meta-analyses are summarised in Additional file [5](#MOESM5){ref-type="media"}.

Secondary outcomes {#Sec12}
------------------

### Plantar fascia thickness {#Sec13}

Values extracted for plantar fascia thickness were from the last time point reported in each trial. Corticosteroid injection was similar to placebo injection (SMD -0.46; 95% CI, − 1.14 to 0.22) \[[@CR24], [@CR46]\], foot orthoses (SMD-0.32; 95% CI − 1.20 to 0.56) \[[@CR61], [@CR64]\], extracorporeal shockwave therapy (SMD 0.33; 95% CI, − 0.15 to 0.80) \[[@CR34], [@CR41], [@CR56]\], and platelet-rich plasma injection (SMD -0.04; 95% CI, − 0.70 to 0.62) \[[@CR36], [@CR60]\] (Fig. [19](#Fig19){ref-type="fig"}). Results from trials that could not be pooled in meta-analyses are summarised in Additional file [6](#MOESM6){ref-type="media"}. Fig. 19Meta-analyses for the outcome of plantar fascia thickness. *SMD = standard mean difference; IV = inverse variance; CI = confidence interval*

Sensitivity analysis {#Sec14}
--------------------

A sensitivity analysis was conducted that excluded trials considered to have high risk of bias. For pain, there was sufficient data for meta-analysis from three trials \[[@CR20], [@CR24], [@CR46]\], which found corticosteroid injection is similar to placebo injection in the short (SMD -0.28; 95% CI, − 0.71 to 0.16) and medium terms (SMD -0.23; 95% CI, − 0.72 to 0.28). No data were available for meta-analysis from other comparators. The findings for 'first step' pain were unchanged with the sensitivity analysis. For function, no data were available, so a sensitivity analysis was not conducted. Finally, the findings for the secondary outcome measure of plantar fascia thickness were unchanged with sensitivity analysis for the comparison to placebo injection only.

Adverse events {#Sec15}
--------------

Adverse events were assessed in 30/47 trials \[[@CR21]--[@CR24], [@CR27]--[@CR32], [@CR34]--[@CR38], [@CR40], [@CR42], [@CR43], [@CR46], [@CR50], [@CR55]--[@CR59], [@CR61]--[@CR65]\]. In 25 of the 30 trials where adverse events were assessed \[[@CR21], [@CR22], [@CR24], [@CR25], [@CR27]--[@CR32], [@CR35], [@CR40], [@CR43], [@CR46], [@CR53], [@CR56], [@CR57], [@CR62]--[@CR65]\], no adverse events were reported. In the remaining 5 trials, the only adverse event that was reported was post-injection pain \[[@CR37], [@CR38], [@CR42], [@CR50], [@CR63]\].

Discussion {#Sec16}
==========

The findings of this systematic review indicate that for the outcome of pain, corticosteroid injection is more effective than autologous blood injection and foot orthoses in the short term (up to 6 weeks), but platelet-rich plasma and dry needling are more effective in the longer term (greater than 12 weeks). For the outcome of function, corticosteroid injection is more effective than physical therapy in the short term. Notably, corticosteroid injection is similar to placebo injection for pain and function.

The finding that corticosteroid injection is similar to placebo injection for the outcome of pain is notable. Many health professionals would perceive a discordance between this finding and reductions in pain observed in clinical practice following corticosteroid injection. However, this may be explained by *non-specific* effects from influences such as natural resolution, regression to the mean, the placebo effect, or expectancy effects \[[@CR69], [@CR70]\]. These non-specific effects cannot be disregarded and our findings may suggest that any *specific* effect from the corticosteroid drug itself is small. Indeed, in similar work relating to knee osteoarthritis, non-specific effects account for almost half of the overall effect observed for corticosteroid injection \[[@CR71]\].

For comparators other than placebo injection, we found corticosteroid injection to be more effective for the reduction of pain than autologous blood injection and foot orthoses in the short term. Although meta-analyses for the remaining comparators in the short term were not statistically significant, there was a general trend for corticosteroid injection to be more effective (based on meaningful effect sizes). However, this trend diminished in the medium to longer term. Statistically significant findings, with moderate to large effect sizes, were found for the comparison to dry needling (SMD of 1.45) and platelet-rich plasma injection (SMD of 0.61). Therefore, compared to the variety of other comparators included in this review, corticosteroid injection is more effective compared to comparators in the short term but not in the longer term. Further research will improve the precision of these estimates and the conclusions that can be drawn, especially regarding the effectiveness of corticosteroid injection in the short term.

For 'first-step' pain, few trials reported this outcome and a meta-analysis was only possible for the comparison between corticosteroid injection and placebo injection, which found that corticosteroid injection was similar to placebo injection in the short term. However, this finding was close to being statistically significant with the upper confidence limit just including zero (SMD -0.33; 95% CI, − 0.68 to 0.01). This finding remained unchanged after excluding trials considered to have a high risk of bias. Given 'first step' pain is a principal complaint of patients with plantar heel pain, it is important that future clinical trials evaluate 'first step' pain as an outcome.

There were few trials that reported function as an outcome, and meta-analyses were only possible for comparisons to physical therapy, foot orthoses, extracorporeal shockwave therapy, platelet-rich plasma injection, and botulinum toxin-A injection. The only significant finding was for the comparison between corticosteroid injection and physical therapy, which found corticosteroid injection to be more effective in the short term. Single trials, and meta-analyses that were not significantly different, tended to find corticosteroid injection was more effective in the short term, but the comparator intervention was found to be more effective in the medium and longer term.

We also investigated the secondary outcome of plantar fascia thickness -- a biological outcome rather than a patient-reported outcome. Meta-analyses found corticosteroid injection was not more effective than other comparators for the reduction of plantar fascia thickness. However, there was a trend for corticosteroid injection to be more effective than placebo injection and for extracorporeal shockwave therapy to be more effective than corticosteroid injection. It is important to note, however, that because this was a secondary outcome, it was not included in our original search strategy, so there is a small chance that additional trials that measured this outcome may have been missed.

The findings above should be interpreted with regard to the quality of the trials that investigated the effectiveness of corticosteroid injection. According to GRADE, the findings of these studies ranged from *very-low* to *moderate* quality, which means we have limited confidence in the findings and they are likely to change when future trials are conducted. Furthermore, most trials (39/47) were at high risk of bias, and when a sensitivity analysis was performed that excluded these trials, there were no significant findings.

Clinical importance {#Sec17}
-------------------

To provide a sense of the clinical worth of these findings, statistically significant results for pain were back-transformed to a 0--100 point visual analogue scale \[[@CR14]\], and compared to the previously calculated minimal important difference value of 8 points (on a 0--100 point scale) \[[@CR72]\] using a pooled standard deviation \[[@CR15]\]. Although this method provides a sense of whether the difference between these interventions is clinically worthwhile, these estimates can be misleading and should be interpreted with caution \[[@CR73]\]. In the short term, corticosteroid injection provided a clinically worthwhile effect when compared to foot orthoses (between-group difference of 12.2 points) and autologous blood injection (between-group difference of 14.8 points). In the longer term, dry needling (between-group difference of 18.9 points) and platelet-rich plasma injection (between-group difference of 10.0 points) provided a clinically worthwhile effect when compared to corticosteroid injection. For function, the clinical worth of corticosteroid injection compared to physical therapy could not be estimated as the minimal important difference values have not been calculated for the outcome measures used by trials in that meta-analysis.

Importantly, these findings were all from trials at high risk of bias, which may exaggerate clinical effectiveness. An example of the influence of bias is the comparison between corticosteroid injection and placebo injection in the short term. After excluding trials at high risk of bias, the estimate of the clinical importance of this comparison (although not statistically significant) reduced from 18.0 points to 4.7 points (on a 0--100 point scale). This reduction should be noted by health professionals, and it reiterates our earlier comment that non-specific effects may influence the reporting of pain.

Limitations and directions for future research {#Sec18}
----------------------------------------------

There was substantial heterogeneity (as indicated by the high *I*^*2*^ values) for most meta-analyses conducted, and this may reflect several recurring methodological issues. First, there were a variety of corticosteroids, combined anaesthetics, injection techniques, and comparators used in the included trials. Second, the mean group size for trials was 28 participants, and most trials did not report a priori sample size calculations. Finally, there was a lack of participant and investigator blinding, which was a common reason that trials were considered to have a high risk of bias. For trials with interventions such as physical therapy, it is almost impossible to blind the participant, however for injectable therapeutic solutions (e.g. autologous blood or platelet-rich plasma), it is possible to achieve participant and investigator blinding \[[@CR74]\]. With these shortcomings in mind, the strength of the overall body of evidence is reduced and the recommendations that can be made are limited.

We found that corticosteroid injection was a safe intervention, with post-injection pain the only reported adverse effect. Two case-series studies published in the 1990s suggested there may be an increased risk of plantar fascia rupture following corticosteroid injection \[[@CR75], [@CR76]\], although no plantar fascia ruptures have been reported for participants who received a corticosteroid injection in the randomised trials included in our review. Long-term adverse effects of a corticosteroid injection are unclear, as few trials reported outcomes beyond 12 weeks. This is an important consideration as there are reports that corticosteroid injection has a deleterious long-term effect on tendon \[[@CR77]\], and one trial that followed participants with lateral epicondylitis for 1 year found that the group that received a corticosteroid injection had more pain than a 'wait and see' group at the conclusion of the trial \[[@CR78]\]. Worryingly, some trials \[[@CR20], [@CR26], [@CR33], [@CR39], [@CR41], [@CR44], [@CR45], [@CR47]--[@CR49], [@CR51]--[@CR54], [@CR60]\] included in our review did not report adverse events, and few reported whether they actively questioned participants about adverse events.

Conclusions {#Sec19}
===========

For the outcome of pain in the short term, we found *low quality* evidence that corticosteroid injection is more effective than autologous blood injection and foot orthoses. In the longer term, we found *very-low quality* evidence that corticosteroid injection is less effective than dry needling and platelet-rich plasma injection. These findings were greater than minimal important difference values, indicating that they are clinically worthwhile. For the outcome of function, we found *low quality* evidence that corticosteroid injection is more effective than physical therapy, but this was only in the short term. Notably, corticosteroid injection was found to have similar effectiveness to placebo injection for pain and function. The impact of bias on these findings was assessed with a sensitivity analysis, which found that corticosteroid injection had similar effectiveness to placebo injection. Further trials that are of low risk of bias will strengthen this evidence.
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